Printer Friendly

Printed from http://www.researchandmarkets.com/reports/1291963

Human Genome Sciences, Inc. (HGSI) - Financial and Strategic SWOT Analysis Review

Description:
Human Genome Sciences, Inc. (HGSI) - Financial and Strategic SWOT Analysis Review

Summary

Human Genome Sciences, Inc. (HGS) is a biopharmaceutical company engaged in the discovery, development and marketing of albumin fusion proteins, antibodies and proprietary technologies. The company’s drugs are targeted against hepatitis C, lupus, inhalation anthrax, cancer and other immune-mediated diseases. It is also engaged in the development of oncology products and genomics-derived small molecule drugs. The company's product under pipeline are BENLYSTA , for the treatment of autoantibody-positive, raxibacumab, for the treatment of inhalation anthrax, Mapatumumab, for treatment of cancer, Darapladib, for the treatment of heart diseases, and Albiglutide, for maintaining the sugar levels. HGS is headquartered at Rockville in Maryland, the US.

Human Genome Sciences, Inc. Key Recent Developments

Aug 08, 2011: Human Genome Sciences Appoints Craig Parker As Senior Vice President, Strategy And Corporate Development
Jul 21, 2011: Human Genome Sciences Reports Total Revenue Of $24.9m For Q2 2011
May 12, 2011: Human Genome Sciences Appoints Allan Baxter To Board
Apr 28, 2011: Human Genome Sciences Reports Net Loss Of $131m For Q1 2011
Mar 14, 2011: Human Genome Sciences Appoints George Morrow To Board

This comprehensive SWOT profile of Human Genome Sciences, Inc. provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
 
Contents:



List of Tables
List of Figures
Section 1 - About the Company
Human Genome Sciences, Inc. - Key Facts
Human Genome Sciences, Inc. - Key Employees
Human Genome Sciences, Inc. - Key Employee Biographies
Human Genome Sciences, Inc. - Major Products and Services
Human Genome Sciences, Inc. - Pharmaceutical Pipeline Products Data
Human Genome Sciences, Inc., Pipeline Products by Therapy Area
Human Genome Sciences, Inc., Pipeline Products by Development Phase
Human Genome Sciences, Inc. - History
Human Genome Sciences, Inc. - Company Statement
Human Genome Sciences, Inc. - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Human Genome Sciences, Inc. - Business Description
Human Genome Sciences, Inc. - SWOT Analysis
SWOT Analysis - Overview
Human Genome Sciences, Inc. - Strengths
Strength - Sturdy Research and Development Activities
Strength - Strategic Partnerships
Strength - World Class Manufacturing Facilities
Weakness - Weak Financial Performance
Weakness - Decreasing Liquidity
Weakness - Increasing Debt
Opportunity - Oncology Products
Opportunity - FDA Approval for BENLYSTA
Opportunity - Changing Demographics
Threat - Tough Credit Market Conditions
Threat - Uncertainties from Clinical R&D Activities
Threat - Stringent Government Regulations
Human Genome Sciences, Inc. - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Human Genome Sciences, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
Human Genome Sciences, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2005 to YTD 2011
Human Genome Sciences, Inc., Recent Deals Summary
Section 5 – Company’s Recent Developments
Aug 08, 2011: Human Genome Sciences Appoints Craig Parker As Senior Vice President, Strategy And Corporate Development
Jul 21, 2011: Human Genome Sciences Reports Total Revenue Of $24.9m For Q2 2011
May 12, 2011: Human Genome Sciences Appoints Allan Baxter To Board
Apr 28, 2011: Human Genome Sciences Reports Net Loss Of $131m For Q1 2011
Mar 14, 2011: Human Genome Sciences Appoints George Morrow To Board
Feb 24, 2011: Human Genome Reports Net Loss Of $87.6m For Q4 2010
Jan 21, 2011: Human Genome Appoints Greg Norden To Board
Dec 14, 2010: Human Genome Sciences Appoints Colin Goddard To Board
Dec 14, 2010: Human Genome Sciences Appoints Colin Goddard To Board
Oct 27, 2010: Human Genome Sciences Reports Net Loss Of $40.9 Million For Q3 2010
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer


List of Tables
Human Genome Sciences, Inc., Key Facts
Human Genome Sciences, Inc., Key Employees
Human Genome Sciences, Inc., Key Employee Biographies
Human Genome Sciences, Inc., Major Products and Services
Human Genome Sciences, Inc., Number of Pipeline Products by Therapy Area
Human Genome Sciences, Inc., Number of Pipeline Products by Development Stage
Human Genome Sciences, Inc., Pipeline Products By Therapy Area and Development Phase
Human Genome Sciences, Inc., History
Human Genome Sciences, Inc., Subsidiaries
Human Genome Sciences, Inc., Key Competitors
Human Genome Sciences, Inc., Ratios based on current share price
Human Genome Sciences, Inc., Annual Ratios
Human Genome Sciences, Inc., Interim Ratios
Human Genome Sciences, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
Human Genome Sciences, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2005 to YTD 2011
Human Genome Sciences, Inc., Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios


List of Figures
Human Genome Sciences, Inc., Pipeline Products by Therapy Area
Human Genome Sciences, Inc., Pipeline Products by Development Phase
Human Genome Sciences, Inc., Performance Chart (2006 - 2010)
Human Genome Sciences, Inc., Ratio Charts
Human Genome Sciences, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011
Human Genome Sciences, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2005 to YTD 2011
 
Companies Mentioned
Depomed, Inc.
PriceSpective Ltd.
AMN Healthcare Services, Inc.
AmSurg Corp.
IMMUNOMEDICS, INC
GlaxoSmithKline plc
Amgen Inc.
Novartis AG
ZymoGenetics, Inc.
 
Ordering:
Order Online - visit http://www.researchandmarkets.com/reports/1291963

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Page 1 of 2
Printed Apr 17th 2014
11:47:38 AM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

Human Genome Sciences, Inc. (HGSI) - Financial and Strategic SWOT Analysis Review

Web Address

http://www.researchandmarkets.com/reports/1291963

Office Code

OC8DINPQPQRWUW

 

Report Formats

Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Site License EUR 184
Electronic (PDF) - Enterprisewide EUR 276
Electronic (PDF) - Single User EUR 92

Contact information

Please enter all the information below in block capitals.

Title:
Mr Mrs Dr Miss Ms Prof
First Name:
Last Name:
Email Address:
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2
Printed Apr 17th 2014
11:47:38 AM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:
Cardholder's Signature:
Expiry Date:
/
Card Number:
CVV Security Code:
Issue date:
/ (Diners Club only)
 
Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

 
Pay by Wire Transfer:

Please transfer funds to:

Account Number:
83313083
Sort Code:
98-53-30
Swift Code:
ULSBIE2D
IBAN Number:
IE78ULSB98533083313083
Bank Address:
Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.
 

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)